Gibbs, Lisa
September 2001
Money;Sep2001, Vol. 30 Issue 9, p118
Details the trip of Americans who go to Canada to buy prescription drugs because of the high cost of drugs in the United States. How prescriptions can be filled for a three month supply and one refill; Issue of legality of the process, according to the U.S. Food and Drug Administration; Focus on the DoctorSolve Healthcare Solutions prescription clinic in Surrey, British Columbia, which was cofounded by Dr. Paul Assad; Reasons for the differences in drug prices in Canada and the U.S. INSET: SAVING MONEY AT HOME.


Related Articles

  • Controlling Spending for Prescription Drugs. Altman, Stuart H.; Parks-Thomas, Cindy // New England Journal of Medicine;3/14/2002, Vol. 346 Issue 11, p855 

    Editorial. Focuses on the cost of prescription drugs in the United States. Problems with the cost of drugs for those who do not have health insurance; Cost of drugs for the elderly; Study in this issue by Lewis et al on discount drug programs for the elderly; How improving the affordability of...

  • Drug cards offer big discounts, confusion. Murphy, Tom // Indianapolis Business Journal;4/19/2004, Vol. 25 Issue 6, p21 

    Provides information on Medicare-approved prescription discount cards in the U.S. Total number of private sponsors preparing the discount cards for use starting June 1, 2004; Decision of several pharmaceutical companies to extend discounts on their own drugs to people who have the cards;...

  • Rx price increases slow.  // Drug Topics;12/13/93, Vol. 137 Issue 23, p78 

    Reports that prescription drug prices rose at a slower rate during the first nine months of 1993 compared with the same periods in 1992 and 1993.

  • Drug companies face pressure on profits. Josefson, Deborah // BMJ: British Medical Journal (International Edition);1/12/2002, Vol. 324 Issue 7329, p65 

    Reports on pressure related to profits facing major pharmaceutical corporations in the United States. Expected impact on drug companies such as Merck, Bristol-Myers Squibb, Eli Lilly, Schering-Plough, and Pharmacia; Impact on popular prescription brand name drugs and their generic equivalents;...

  • The high cost of medicines in Ireland. Tilson, Lesley; McGowan, Bernadette; Bennett, Kathleen; Barry, Michael // European Journal of Health Economics;Dec2004, Vol. 5 Issue 4, p341 

    This study compared the prices of prescription medicines in Ireland to those in other countries to determine potential cost savings on the largest community drug scheme if an alternative pricing mechanism were adopted. The analysis covered a sample of 39 drugs (44.8% of the total ingredient...

  • Drug price regulation under consumer moral hazard. Two-part tariffs, uniform price or third-degree price discrimination? Felder, Stefan // European Journal of Health Economics;Dec2004, Vol. 5 Issue 4, p324 

    Drug price differences across national markets as they exist in the EU are often justified by the concept of Ramsey prices: with fixed costs for R&D, the optimal mark-ups on marginal costs are inversely related to the price elasticity in the individual markets. This well-known result prevails if...

  • Prescribing data shows slowdown in drug spending. Polak, Monika // GP: General Practitioner;5/3/2004, p5 

    The increase in prescribing costs has slowed down, according to data from the Prescription Pricing Authority (PPA) published last week. The PPA prescribing cost analysis for 2003 showed that almost 650 million prescription items were dispensed in 2003, costing just over pounds 7.51 billion....

  • E&Y Division Launching Program To Help Health Plans Manage Prescription Expenses.  // Insurance Advocate;4/8/2002, Vol. 113 Issue 13, p38 

    Announces the launch of the RxManager service from Ernst & Young LLP, to help health plans manage prescription expenses on March 25, 2002.

  • Teriflunomide gets NICE recommendation.  // PharmacoEconomics & Outcomes News;Feb2014, Issue 695, p11 

    The article reports that the British National Institute for Health and Care Excellence (NICE) has recommended the use of teriflunomide tablets to treat relapsing-remitting multiple sclerosis (MS). It notes that teriflunomide will only be administered at a discounted price to patients who do not...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics